The Food and Drug Administration approved Narcan, a naloxone hydrochloride nasal spray, for over-the-counter nonprescription, use, the first naloxone product approved for use without a prescription. Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard treatment for opioid overdose, the agency said in a statement. The timeline for availability and price of the product is determined by the manufacturer. The FDA granted the OTC approval of Narcan to Emergent BioSolutions.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EBS:
- U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
- Emergent BioSolutions falls -10.3%
- Emergent BioSolutions falls -11.5%
- Emergent BioSolutions downgraded to Underweight from Neutral at JPMorgan
- Emergent Bio Up as Street Biggies Lap Up Shares